Amarin Corp Plc (AMRN)

[wikthor]

The key remains the estimated peak sales. If Novartis believes it will exceed $2B, it has paid slightly less than that x5 peak revenue. And it is a common multiple in BO & merger
https://reconstrategy.com/2022/08/an-innovative-sales-strategy-for-a-pivotal-drug-leqvio/

What`s the target population of Vacespa/Vazkepa?
What`s that sales peak?
That is the key why Denner has gotten into it

And before talking about generics, US population is 330m, Western Europe +600 to add China, Canada, Australia, New Zealand...
Neither do you count the rest of the investigations (a molecule, many applications to investigate) or the combo pill.

Adding everything up, that's why I'm still here and I won't leave until the BO or that peak sales is reached.